Sign in

CIK 0001754068

  • Non-accelerated filer
  • Smaller reporting company

Kalaris Therapeutics, Inc.

Sign in to watch
Ticker
KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831971007
Phone
+1 650-249-2727
Business address
400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
Former names
Allovir, Inc., ViraCyte, Inc.
  1. 4 Grant or award Sinha Vikas acquired 100,000 shares (grant or award)
  2. 4 Grant or award General Counsel acquired 15,000 shares (grant or award)
  3. 4 Grant or award Chief Executive Officer acquired 100,000 shares (grant or award)
  4. 4 Open-market sale Chief Commercial Officer sold 15,590 shares at $8.30 ($129,473)
  5. 4 Grant or award Chief Accounting Officer acquired 20,000 shares (grant or award)
  6. 3 Insider Initial Statement of Ownership
  7. 3 Insider Initial Statement of Ownership
  8. 4 Grant or award Sinha Vikas acquired 3,253,796 shares (grant or award)
  9. 4 Grant or award Director acquired 3,253,796 shares (grant or award)
  10. 4 Grant or award Director acquired 8,152,247 shares (grant or award)
  11. 4 Grant or award Director acquired 3,253,796 shares (grant or award)
  12. 4 Grant or award Director acquired 3,253,796 shares (grant or award)
  13. 4 Open-market sale Atillasoy Ercem sold 1,533 shares at $5.38 ($8,245)
  14. 4 Open-market sale Director sold 4,227 shares at $5.33 ($22,528)
  15. 4 Open-market sale Sinha Vikas sold 1,432 shares at $5.21 ($7,467)
  16. 4 Open-market sale Atillasoy Ercem sold 563 shares at $5.21 ($2,936)
  17. 4 Open-market sale Chief Commercial Officer sold 1,058 shares at $5.21 ($5,517)
  18. 4 Grant or award Chief Accounting Officer acquired 10,500 shares (grant or award)
  19. 4 Grant or award General Counsel acquired 14,000 shares (grant or award)
  20. 4 Grant or award Director acquired 29,400 shares (grant or award)

Page 11 of 19 · 363 filings